Elevai Labs, Inc. Common Stock
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the med… Read more
Elevai Labs, Inc. Common Stock (ELAB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.176x
Based on the latest financial reports, Elevai Labs, Inc. Common Stock (ELAB) has a cash flow conversion efficiency ratio of -0.176x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.49 Million) by net assets ($8.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Elevai Labs, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Elevai Labs, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Elevai Labs, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elevai Labs, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CO.DON AG INH. O.N.
F:CNW
|
N/A |
|
Searchlight Resources Inc
PINK:SCLTF
|
-0.066x |
|
Oasis Crescent Property Fund
JSE:OAS
|
-0.008x |
|
Direxion Daily AMD Bull 2X Shares
NASDAQ:AMUU
|
N/A |
|
ACURX PHARMACEUT. DL-001
F:3ZO
|
N/A |
|
MKB Nedsense N.V.
LSE:0ML7
|
N/A |
|
TRACTOR SUPPLY (TR4.SG)
STU:TR4
|
0.038x |
|
KOMATSU
MU:KOM1
|
0.049x |
Annual Cash Flow Conversion Efficiency for Elevai Labs, Inc. Common Stock (2020–2024)
The table below shows the annual cash flow conversion efficiency of Elevai Labs, Inc. Common Stock from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.66 Million | $-5.49 Million | -0.824x | +30.80% |
| 2023-12-31 | $3.83 Million | $-4.56 Million | -1.191x | +15.06% |
| 2022-12-31 | $1.13 Million | $-1.59 Million | -1.402x | +4.42% |
| 2021-12-31 | $450.63K | $-660.93K | -1.467x | -115.93% |
| 2020-12-31 | $-23.59K | $-217.16K | 9.206x | -- |